How much does a 2020 coronavirus medicine cost in Russia?

2024 Author: James Gerald | [email protected]. Last modified: 2023-12-17 14:00

The coronavirus drug Favipiravir may appear in Russia in 2020 ahead of schedule. It received the Russian name "Avifavir", and is now undergoing clinical trials. Despite the fact that the drug is without state registration, it is already being received by patients infected with coronavirus infection participating in the study.

Drug creation

Russia has created the first effective drug called Avivavir against coronavirus infection. The drug has successfully passed clinical trials, and one batch has been sent to hospitals for therapy. During the development of dosage forms against COVID-19, they hoped for this particular drug.

At the heart of the Russian remedy is the Japanese "Favipiravir", which has shown good results in the treatment of those infected with coronavirus infection. A batch for experiments was prepared in Russia at the end of April.

The drug was sent for clinical trials with the participation of 40 volunteers. Patients took medication during treatment for coronavirus. Avifavir has shown good results in the fight against SARS-CoV-2.

The effectiveness of the drug and expert opinion

Nikita Lomakin, chief cardiologist at the Central Clinical Hospital of the Presidential Administration of the Russian Federation, noted that the drug is very effective in treating those infected with a mild degree of illness. Symptoms decrease, and the development of pneumonia decreases.

According to the patient Olga Sorokina, who agreed to take the drug during the trial, on the third day, the state of health improved. The woman was hospitalized with a temperature of 40 ° C and pneumonia.

From the first day she was given Avifavir, and on the third day she felt better. Olga noted that she trusted the doctors and was not worried that she was taking a drug that had not passed state registration.

In most patients, on the third day, the body temperature drops. Fifth, a negative coronavirus test result.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said that Avifavir is a unique drug with a lower level of toxicity and impact on the heart system and kidneys.

If the American "Remdizivir" reduces the average duration of the disease from 15 to 11 days, then the Russian "Avifavir" - by half.

The chairman of the board of directors of the Khimrar Group of Companies noted that a drug of this type blocks the division of the virus inside the body. The cells are not destroyed and the virus does not multiply.

Clinical trials of the drug

On May 21, the Ministry of Health of the Russian Federation approved the final tests of the drug. 330 patients will take part in them. The very first clinical tests of Avifavir, which lasted 10 days, showed:

• drug safety;
• absence of new and unreported side effects;
• the effectiveness of the drug is above 80%;
• high antiviral activity of the agent.

The clinical efficacy of the drug in the fight against the disease caused by the new type of coronavirus has been successfully proven. Clinical trials will be completed in 14 days, but mass production has already started. There is currently no information about where you can buy the drug and how much it costs.

According to the general director of the Russian Direct Investment Fund, where a large batch of Russian Avifavir is produced, the tablets will be delivered to 30 hospitals in 9 regions of Russia. The second stage of drug testing will begin.

It is planned that Avifavir will appear in infectious diseases clinics in June this year. The Russian Ministry of Health noted that thanks to the positive research results, it will be possible to conduct state registration of a drug for coronavirus as soon as possible and bring it to the market in 2020.

Summarize

1. The first drug that effectively fights coronavirus infection has appeared in Russia. The drug is called "Avifavir". It was created on the basis of the Japanese "Favipiravira".
2. In the course of trials and testing on real patients, it was found that the drug copes with its task. According to research, on the third day of taking the drug, patients have normalized body temperature, on the fifth day - a negative test result for coronavirus.
3. The drug has not yet passed state registration and has not been officially launched on the market. The Ministry of Health of the Russian Federation is confident that the positive research results will help bring the drug's launch date closer.
4. The last stage of testing "Avifavir" with the participation of more than 300 voluntary patients remains. The medicines will be tested in 30 clinics in Russian regions.